Maker of $1,000 Hepatitis C pill looks to cut its cost overseas
NPR - 02/07/2014
Law professor at Northeastern University in Boston, an adviser to , or Health GAP, notes that Gilead allows generic manufacturers to sell its HIV drugs in over 100 countries.
“So why not a similarly large number of countries for the hepatitis C drug?” Baker tells Shots. “An important question to ask is what are their access intentions for countries that have high hepatitis C burdens?”